Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Alterity Therapeutics Limited (ATHE) provides access to the company’s disclosures as a foreign private issuer listed on NASDAQ. Alterity files reports under the Securities Exchange Act of 1934, including its annual report on Form 20‑F and current reports on Form 6‑K, and describes itself in these documents as a development stage enterprise focused on neurodegenerative diseases.
For investors following this clinical stage biotechnology company, Form 6‑K filings are particularly important. They often include material that has been released to the Australian Securities Exchange, such as quarterly Appendix 4C cash flow reports, clinical trial updates for ATH434 in Multiple System Atrophy (MSA), regulatory designations like U.S. FDA Fast Track status, and information on capital raisings or strategic placements. Other 6‑K submissions may contain meeting results, presentations to shareholders, and notices related to board or director changes.
Alterity’s Form 20‑F annual report (when filed) typically consolidates information on its business overview, risk factors, research and development focus on Parkinsonian and other neurodegenerative disorders, and its status as a clinical stage company. These filings complement the company’s scientific and clinical communications by outlining its segment focus on research and development and its listing arrangements on the Australian Securities Exchange and NASDAQ.
On Stock Titan, this page surfaces Alterity’s SEC filings as they are made available from EDGAR and pairs them with AI‑powered summaries to help readers interpret technical language. Users can quickly see the purpose of each 6‑K or 20‑F, identify items related to ATH434 clinical data, regulatory interactions, cash flow disclosures, and corporate governance, and then drill into the full text for detailed review.
Alterity Therapeutics Limited has appointed Ms Ann Cunningham as an independent Non-Executive Director to its Board, effective 17 April 2026. She brings more than 25 years of global pharmaceutical and biotechnology experience, with deep expertise in commercial strategy across neurodegenerative disease and psychiatry.
Cunningham has held senior roles at Eli Lilly and Teva Pharmaceuticals, leading marketing and sales teams and overseeing neurodegenerative and psychiatry portfolios. Her appointment comes as Alterity prepares to advance its lead asset ATH434 into Phase 3 development for Multiple System Atrophy and move toward potential commercialisation.
Alterity Therapeutics Limited filed a Form 6-K highlighting a scientific milestone for its lead drug candidate ATH434. Daniel Claassen, M.D., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will present late-breaking clinical data at the American Academy of Neurology Annual Meeting in Chicago.
The oral presentation, titled “ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale,” is scheduled for Tuesday, April 21, 2026 at 6:21 PM. ATH434 has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy and additional positive data in an open-label Phase 2 trial in advanced disease.
Alterity is a clinical stage biotechnology company focused on disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders, and is preparing to initiate a Phase 3 pivotal trial in MSA. The company also maintains a broader discovery platform targeting underlying pathology in neurodegenerative diseases.
Alterity Therapeutics Ltd Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings in the company. He reports direct ownership of 11,688,312 ordinary shares and indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees (Australia) Limited. He also holds several option grants over ordinary shares with exercise prices ranging from $0.0030 to $0.0280 and expirations between August 2026 and August 2030, indicating a sizable long-term equity position.
Alterity Therapeutics is hosting a virtual key opinion leader webcast to discuss ATH434 for treating Multiple System Atrophy (MSA), a rare, rapidly progressive neurodegenerative disease with no approved treatment. The event will feature neurologists Roy Freeman, MD, and Daniel Claassen, MD, MS, alongside CEO David Stamler, MD.
The company describes ATH434 as its lead asset and notes that it has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA, with additional positive data from an open label Phase 2 study in advanced MSA. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA and continues to develop a broader drug discovery platform targeting the underlying pathology of neurodegenerative diseases.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan has filed an initial Form 3 showing his indirect holdings in the company. The filing reports 4,545,455 ordinary shares held indirectly through Montoya Pty Ltd <Buttercup A/C>.
He also indirectly holds listed options over 1,515,152 ordinary shares with a conversion price of $0.028 per share, expiring on 26 February 2027, and unlisted options over 50,000,000 ordinary shares with a conversion price of $0.010 per share, expiring on 30 December 2027. The Form 3 records these positions as existing holdings rather than new market purchases or sales.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy filed an initial Form 3, which is a required disclosure of insider holdings. The filing lists him as a director but shows no reportable transactions, exercises, gifts, or restructurings and no derivative positions in this snapshot.
Alterity Therapeutics director Peter Ashley Marks filed an initial Form 3 reporting his beneficial holdings in the company. He indirectly holds 1,818,182 Ordinary shares through Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>. He also holds listed options over 606,061 Ordinary shares with a conversion price of $0.028 per share expiring on 26 Feb 2027, and unlisted options over 30,000,000 Ordinary shares with a conversion price of $0.010 per share expiring on 30 Dec 2027.
Alterity Therapeutics Chief Financial Officer Abby Sarah Macnish Niven filed an initial ownership report detailing indirect equity interests in the company held through CASAM Investments Pty Ltd.
The filing lists 454,545 ordinary shares and a listed option expiring on 26 Feb 2027 over 151,510 underlying ordinary shares at an exercise price of 0.0280 per share. These entries describe existing indirect holdings rather than new market purchases or sales.
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA). After a Type C Meeting, the FDA provided written feedback supporting the company’s clinical pharmacology and non-clinical plans for a planned Phase 3 pivotal trial.
The company now aims to secure FDA agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-year 2026. ATH434 has already shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and additional positive data in an open-label Phase 2 study in advanced MSA, and Alterity is preparing to initiate Phase 3.